Systems Biology for Drug Discovery

1

• Systems Biology for Drug Discovery

www.GeneGo.com
SoCALBSI 2004
Lien Chung
2
Company Overview

• Locations St. Joseph, MI
• San Diego, Ca Moscow, Russia
• Founded 2000
• Technology Systems Reconstruction
• Software MetaCoreTM, MetaDrugTM
• Partners SDSC, Affymetrics, Pathway Diagnostics,
  Invitrogen, Michigan Center for Biological
  Information (MCBI)

3
Management

• Hwa Lim, PhD
• Chairman of the Board
• Tatiana Nikolskaya
• Chief Scientific Officer (CSO) and Founder
• Sean Ekins, PhD
• Vice President of Computational Biology
• Andrei Bugrim, Ph.D.
• Chief Operating Officer (COO)
• Julie Bryant
• Vice President, Development and Sales

4
Motivations for Systems Biology Approach
Road Blocks

• Advent of high-throughput technologies have led
  an enormous amount of disease-related HT data
  that need to be mined for information
• Drug discovery progressing slowly because of
  inability to link genotypic data to phenotypic
  manifestations

Systems Biology Solution

• Construction of networks and pathways to show
  interactions between genes, proteins, and
  metabolites involved in the diseased state
• Knowledge of mechanisms and metabolic pathways
  helpful in identifying biomarkers, developing new
  therapeutic targets, and elucidating disease
  pathways

5
MetaCoreTMA Database of Human Metabolism and
Regulation

• Unique pathway-centered structure built upon
  Oracle databases
• Pathways generated from the incorporation of
  various high-throughput sources
• Can integrate users own HT data and overlay them
  onto existing pathways
• Ability to edit existing pathways according to
  user-defined parameters

6
MetaCoreTM
Types of HT sources
Microarray Expression Data
Protein interaction data
Literature
Phenotypic Data
SAGE
Disease Databases
7
Types of Visualizations

• Tissue-specific maps
• Metabolic pathways
• Cell-signaling pathways
• Regulatory networks
• Toxicity data and pathways
• Disease data

8
Regulatory Pathways w/ HT Data
9
Visualization of Networks
10
Disease Maps
11
MetaDrugTM

• Currently under development
• Software tool for drug prediction and ADME/Tox
  in-silico testing
• Will provide information about xenobiotic
  metabolism (fate of foreign compounds in body)
• Software for predicting toxicity of potential
  drugs

12
Superiority to Competitors

• Tools to incorporate ones own high-throughput
  data and dynamically visualize on maps and
  pathways
• User has full control of the parameters of the
  data mining procedure
• User can Add/Edit protein or gene interactions
  and add references
• Non-redundancies, more than 10,000 synonyms
  resolved

13
Competitors
14
GeneGos Market

• Biotech Companies
• Pharmaceutical Companies
• Private Research Institutions
• Educational Institutions

15
GeneGos Future

• Release of MetaDrug will boost its financial
  outlook
• Technology and software is unique but it needs to
  make partnerships in order to expand its
  clientele
• Expanding beyond creating databases may also
  attract other types of investors
• Possible merging with a big company may be
  necessary to sustain their presence